This is a Phase 2 single site randomized clinical trial (RCT) to be supported by a new
NIH-NIAAA grant, R01-AA029113-01, to assess the efficacy of Prazosin (16mg/day) versus
Placebo over a 12 week treatment period, followed by a 1- and 3- month assessments
post-treatment for individuals with Alcohol Use Disorder (AUD) and history of past or current
evidence of alcohol withdrawal symptoms. If medical detoxification is required for any
patient, patients would be enrolled after medical detoxification. for those not requiring
detoxification, they will be enrolled directly without any requirement of alcohol abstinence.
All patients will be provided behavioral counseling weekly with a trained counselor to
support recovery during the trial. Primary outcomes will be percent of subjects no heavy
drinking days (PSNHDD) and %of any drinking and heavy drinking days as well as secondary
outcomes of craving, mood, anxiety and sleep problems.